Mycoplasma bovis VspA antibody and antigen (recombinant protein)

Diagnostic anti-Mycoplasma bovis VspA antibodies pairs and antigen for animal health (animal Bovines/Cattle infectious disease mastitis, arthritis and pneumonia) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Ruminants disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P073-Tg001-Ag01 Recombinant Mycoplasma bovis VspA protein $3090.00
GMP-VT-P073-Tg001-Ab01 Anti-Mycoplasma bovis VspA mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P073-Tg001-Ab02 Anti-Mycoplasma bovis VspA mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P073-Tg001-Ab03 Anti-Mycoplasma bovis VspA human monoclonal antibody (mAb) $3090.00
GMP-VT-P073-Tg001-Ab04 Anti-Mycoplasma bovis VspA human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P073-Tg001-Ag01
Product Name Recombinant Mycoplasma bovis VspA protein
Pathogen Mycoplasma bovis
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Mycoplasma bovis VspA antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Mycoplasma bovis level test of animal Bovines/Cattle infectious disease with mastitis, arthritis and pneumonia.
Tag His
Product description Recombinant Mycoplasma bovis VspA proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P073-Tg001-Ab01,GMP-VT-P073-Tg001-Ab02
Pathogen Mycoplasma bovis
Product Name Anti-Mycoplasma bovis VspA mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Mycoplasma bovis VspA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma bovis antibodies in Mycoplasma bovis level test of animal Bovines/Cattle infectious disease with mastitis, arthritis and pneumonia.
Product description Anti-Mycoplasma bovis VspA mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma bovis antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P073-Tg001-Ab03,GMP-VT-P073-Tg001-Ab04
Pathogen Mycoplasma bovis
Product Name Anti-Mycoplasma bovis VspA human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Mycoplasma bovis VspA antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Mycoplasma bovis antibodies in Mycoplasma bovis level test of animal Bovines/Cattle infectious disease with mastitis, arthritis and pneumonia.
Product description Anti-Mycoplasma bovis VspA mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Pathogen Information


    Mycoplasma bovis is a bacterial pathogen that primarily infects cattle, causing significant economic losses in the dairy and beef industries. M. bovis is commonly referred to as a mycoplasma, which is a prokaryotic bacterium belonging to the class Mollicutes. Unlike most bacteria, mycoplasmas lack a cell wall and are surrounded only by a cytoplasmic membrane. The genome size of M. bovis is approximately 1.1 Mb, and it expresses multiple adhesins and virulence factors, including the Vsp family of surface proteins, which enhance its ability to attach to and invade host cells.

    Mycoplasma bovis has a small genome, with several genes encoding ribosomal RNA (16S rRNA), ATP synthase, and metabolic enzymes. M. bovis is an obligate aerobe, requiring oxygen for respiration, and it can utilize glucose, glycerol, or arginine as a source of energy. However, M. bovis has limited biosynthetic capabilities, requiring many nutrients from the host environment.

    Mycoplasma bovis primarily infects cattle, though it has been identified in other domestic and wild animals. Young calves are particularly susceptible to the pathogen, as their immune systems are not fully developed. Infection with M. bovis can result in a range of clinical diseases, including respiratory infections, mastitis, arthritis, and pneumonia. The severity of these diseases can depend on factors such as host susceptibility, environmental stressors, and the strain of M. bovis involved in the infection.

    Respiratory infections caused by M. bovis can range from mild to severe, with symptoms including fever, coughing, and nasal discharge. These infections can be complicated by secondary bacterial infections or pneumonia, which can lead to more severe respiratory disease. Mastitis, which is an inflammation of the mammary gland, can be caused by M. bovis infections. Mastitis is a common disease in dairy cows and can significantly impact milk production. Arthritis caused by M. bovis generally affects the joints of young calves, resulting in lameness and reduced mobility. Pneumonia caused by M. bovis can also occur in older animals and can lead to severe respiratory distress.

    The diagnosis of M. bovis infections can be challenging, as the pathogen is difficult to culture and can be missed by traditional diagnostic methods. Diagnostic methods for M. bovis include culture, PCR, and serological tests. Culture-based methods require specialized media and are time-consuming. PCR-based assays target various genes, including the 16S rRNA gene and the Vsp family of genes. Serological tests target specific proteins on the surface of M. bovis, such as the P48 protein, which is a major antigenic target for serological diagnosis.

    Management of M. bovis infections can be challenging, especially in herd settings. Control measures should focus on preventing the introduction of infected animals into the herd, maintaining good hygiene practices, and testing and culling infected animals. Additionally, vaccination against M. bovis has shown some efficacy in reducing the incidence and severity of respiratory disease in cattle.

    In conclusion, Mycoplasma bovis is an important pathogen that primarily infects cattle, causing significant economic losses in the dairy and beef industries. The pathogen is a prokaryotic bacterium belonging to the class Mollicutes, with a small genome size and limited biosynthetic capabilities. The pathogen expresses multiple adhesins and virulence factors, including the Vsp family of surface proteins, which enhance its ability to attach to and invade host cells. Clinical diseases caused by M. bovis include respiratory infections, mastitis, arthritis, and pneumonia. Accurate diagnosis of M. bovis infections is essential for proper management, and diagnostic methods include culture, PCR, and serological tests. Control measures should focus on preventing the introduction of infected animals into the herd, maintaining good hygiene practices, and testing and culling infected animals. Vaccination against M. bovis has shown some efficacy in reducing the incidence and severity of respiratory disease in cattle and is recommended in high-risk herds.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.